Skip to main content

Drug Interactions between Avandia and rifabutin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

rifabutin rosiglitazone

Applies to: rifabutin and Avandia (rosiglitazone)

MONITOR: Coadministration with inducers of CYP450 2C8 may decrease the plasma concentrations of rosiglitazone, which is primarily metabolized by the isoenzyme. In 10 healthy volunteers given the potent enzyme inducer rifampin (600 mg once daily) for six days prior to coadministration with a single 8 mg dose of rosiglitazone on day 7, mean rosiglitazone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 31% and 66%, respectively, while elimination half-life decreased from 3.9 to 1.5 hours. Apparent oral clearance of rosiglitazone increased about 3-fold with rifampin pretreatment. These changes were observed in every subject. Similar results were reported for rosiglitazone 4 mg in another pharmacokinetic study.

MANAGEMENT: Because the antidiabetic effect of rosiglitazone is dose- and concentration-dependent, patients treated concomitantly with a CYP450 2C8 inducer may require a higher dosage of rosiglitazone. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of the CYP450 2C8 inducer, and the rosiglitazone dosage adjusted as necessary.

References

  1. (2001) "Product Information. Avandia (rosiglitazone)." SmithKline Beecham
  2. Baldwin SJ, Clarke SE, Chenery RJ (1999) "Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone." Br J Clin Pharmacol, 48, p. 424-32
  3. Park JY, Kim KA, Kang MH, Kim SL, Shin JG (2004) "Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects." Clin Pharmacol Ther, 75, p. 157-62
  4. Niemi M, Backman JT, Neuvonen PJ (2004) "Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone." Clin Pharmacol Ther, 76, p. 239-49
  5. Scheen AJ (2007) "Pharmacokinetic interactions with thiazolidinediones." Clin Pharmacokinet, 46, p. 1-12
  6. Totah RA, Rettie AE (2005) "Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance." Clin Pharmacol Ther, 77, p. 341-52
View all 6 references

Switch to consumer interaction data

Drug and food interactions

Moderate

rosiglitazone food

Applies to: Avandia (rosiglitazone)

GENERALLY AVOID: Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes. Hypoglycemia most frequently occurs during acute consumption of alcohol. Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise. The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia. Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion. By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia. Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes. A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.

MANAGEMENT: Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis. Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan. Alcohol should not be consumed on an empty stomach or following exercise.

References

  1. Jerntorp P, Almer LO (1981) "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand, 656, p. 33-6
  2. Jerntorp P, Almer LO, Holin H, et al. (1983) "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol, 24, p. 237-42
  3. Barnett AH, Spiliopoulos AJ, Pyke DA, et al. (1983) "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia, 24, p. 213-5
  4. Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A (1987) "Interaction of ethanol and glipizide in humans." Diabetes Care, 10, p. 683-6
  5. (2002) "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals
  6. (2002) "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals
  7. "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  8. Skillman TG, Feldman JM (1981) "The pharmacology of sulfonylureas." Am J Med, 70, p. 361-72
  9. (2002) "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care, 25(Suppl 1), S50-S60
  10. Cerner Multum, Inc. "UK Summary of Product Characteristics."
View all 10 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer